The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Government Proposes Rule Overhauling Drug Industry Rebate System

U.S. Government Proposes Rule Overhauling Drug Industry Rebate System

February 5, 2019 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters)—The U.S. government proposed a rule to end the industry-wide system of after-market discounts called rebates that pharmacy benefit managers receive from drugmakers, a practice that has been under scrutiny.

You Might Also Like
  • Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
  • Pfizer Plans to Increase U.S. Drug Prices in January
  • Eli Lilly Backs U.S. Proposal on Drug Rebates to Lower Costs

If finalized, the rule would change a system that has been in place for decades and that increasingly has been criticized for obfuscating the real price of prescription drugs.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Administration of U.S. President Donald Trump has been promising to lower the cost of prescription drugs for consumers, who have seen their out-of-pocket expenses rise each year with higher list prices of pharmaceuticals.

The proposed rule from the U.S. Department of Health and Human Services would apply to companies like Cigna Corp’s Express Scripts and CVS Health Corp that manage pharmacy benefits for employers and insurers, as well as companies, such as Humana Inc., that manage Medicare prescription drug benefits, and Medicaid managed care organizations.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The government has been considering such a change since last year.

The Trump administration’s proposed rule would allow rebates on prescription drugs to be offered directly to patients, and it would allow pharmacy benefit managers to establish fixed fee service arrangements with drugmakers that could replace their revenue from rebates.

Filed Under: Drug Updates, Pharma Co. News Tagged With: PBM rebate system, pharmacy benefit managers (PBMs), Prescription drugs

You Might Also Like:
  • Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
  • Pfizer Plans to Increase U.S. Drug Prices in January
  • Eli Lilly Backs U.S. Proposal on Drug Rebates to Lower Costs
  • FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.